PFS after anti-EGFR antibody therapy was compared between four groups of GWMS (HMCC and LMCC) classified by this assay and the primary lesion site (right-sided and left-sided CRC), and the results, showed that GWMS was able to predict the efficacy and prognosis of anti-EGFR antibody therapy with greater accuracy than the location of the primary tumor (Figure 2). The gene discussed is EGFR; the disease is colorectal carcinoma.